التفاصيل البيبلوغرافية
| العنوان: |
Thrombolysis as first-line therapy for Medtronic/HeartWare HVAD left ventricular assist device thrombosis. |
| المؤلفون: |
Dimitrov, Kamen, Maier, Julian, Sandner, Sigrid, Riebandt, Julia, Wiedemann, Dominik, Moayedifar, Roxana, Schlöglhofer, Thomas, Angleitner, Philipp, Niederdöckl, Jan, Schima, Heinrich, Tschernko, Edda, Laufer, Guenther, Zimpfer, Daniel |
| المصدر: |
European Journal of Cardio-Thoracic Surgery; Dec2020, Vol. 58 Issue 6, p1182-1191, 10p |
| مصطلحات موضوعية: |
THROMBOSIS, THROMBOLYTIC therapy, HEART transplantation, KIDNEY exchange, THROMBOEMBOLISM, HEART assist devices |
| مستخلص: |
OBJECTIVES Open in new tab Download slide Open in new tab Download slide We reviewed our institutional experience with intravenous thrombolysis (TL) as first-line therapy in patients with Medtronic/HeartWare HVAD left ventricular assist device pump thrombosis (PT). METHODS From March 2006 to November 2018, 30 Medtronic/HeartWare HVAD left ventricular assist device patients had 48 PT events. We analysed outcomes with intravenous Alteplase as a first-line therapy for PT. Pump exchange or urgent heart transplantation was only considered after the failure of TL or existing contraindications to TL. RESULTS TL was used as the first-line therapy in 44 PT events in 28 patients without a contraindication to TL. TL was successful in 61.4% of PT events. More than 1 cycle of TL was necessary in 55.6% of events. The combined success of TL and heart transplantation or device exchange was 81.8%. In 15.9% of events, PT was fatal. Causes of death were severe complications (9.1%) related to TL or discontinuation of therapy for multi-organ failure (6.8%). Intracranial bleeding and arterial thromboembolism were observed in 4.5% and 11.5% of the PT events after TL. CONCLUSIONS Intravenous TL as a first-line therapy for PT in Medtronic/HeartWare HVAD patients can be a reasonable treatment option and does not preclude subsequent heart transplantation or device exchange. However, thromboembolic and bleeding complications are common. The decision to perform TL or device exchange should, therefore, be made on an individual basis after balancing the risks and benefits of different treatment approaches. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Cardio-Thoracic Surgery is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder